(Q33400583)

26 July 2017

Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1 reference

Yun Hou

1

1 reference

26 July 2017

Hua-qing Wang

series ordinal

2

1 reference

26 July 2017

Yi Ba

series ordinal

3

1 reference

26 July 2017

3 April 2012

1 reference

26 July 2017

1 reference

26 July 2017

29

1 reference

26 July 2017

4

1 reference

26 July 2017

2409-2416

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2

26 July 2017

0 references

cites work

Current treatment strategy of diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Gemcitabine and cisplatin in refractory malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0211-2

Preclinical, pharmacologic, and phase I studies of gemcitabine

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22476761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22476761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-012-0211-2

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference